Brimonidine for myopia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Dec 2022: Trial registered, NCT05656027
  2. 19 Dec 2022: Trial started, NCT05656027

The trials

NCT05656027: Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia

State
Completed
Phase
Phase 3
People
469 taking part
Started
19 Dec 2022
Primary completion
15 Dec 2023
Arms
Brimonidine ophthalmic solution dosed bilaterally
Results
Posted on the registry
  1. 19 Dec 2022: Trial registered
  2. 19 Dec 2022: Trial started
  3. 25 Jan 2024: Trial completed
  4. 25 Feb 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.